ArticleDiscover oncology2025
miR-126-5p suppresses HeLa and Ishikawa cell proliferation and migration via the RICTOR/AKT pathway.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesUterine cancer is a leading gynecological malignancy with increasing incidence and mortality rates, particularly in regions such as the United States and China. Despite advancements in treatment, current therapeutic strategies are often limited by tumor heterogeneity, therapy resistance, and a lack of targeted treatment options. These challenges underscore the urgent need for novel therapeutic approaches to improve patient outcomes. This study aims to investigate the role of miR-126-5p in uterine cancer pathogenesis, focusing on its potential as a therapeutic target to address these limitations.
methodThe study employed HeLa (cervical cancer) and Ishikawa (endometrial adenocarcinoma) cell lines to evaluate the effects of miR-126-5p on cell proliferation, migration, and apoptosis. The molecular mechanisms underlying these effects were further explored by examining the involvement of the RICTOR/AKT signaling pathway.
resultmiR-126-5p was demonstrated to significantly inhibit cell proliferation and migration while promoting apoptosis in both HeLa and Ishikawa cell lines. These effects were mediated through the RICTOR/AKT signaling pathway, with no involvement of the RICTOR/PCK pathway.
conclusionThe findings reveal miR-126-5p as a critical regulator of uterine cancer progression and a promising therapeutic target. By addressing the limitations of current therapies, this study provides a foundation for the development of miRNA-based treatments, offering new hope for improving outcomes in uterine cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.